Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.08 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: satralizumab, tocilizumab, levilimab +2 | 0.90 |
| trials ClinicalTrials.gov | 1 Parkinson's trial, 0 stopped | 1.00 |
| literature PubMed | 15 Parkinson's papers of 3,066 | 0.64 |
| pathways Reactome | 7 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 3138
Sealed predictions
- IL6R in dopamine neurons, braak+0.23 (p 0.545) → -0.60 (p 0.088)receipt 3145
Swarm cases
receipt 3145: IL6R in dopamine neurons, braak
- power
- full sample -0.19 (p 0.460, n 18), 95% CI -0.60 to +0.31. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.21 (p 0.398, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.27 (p 0.281, n 18). could be the mix.
- skeptic
- leave-one-out range -0.29 to -0.08, sign flips 0; without severely affected donors -0.19 (p 0.460, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for IL6R in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts